Last updated: February 25, 2026
What is the scope of Patent CA2732803?
Patent CA2732803 is a Canadian drug patent related to a novel pharmaceutical composition or method. The patent's scope involves a specific formulation, compound, or therapeutic application. The issued patent covers claims broadly to include the composition’s structure, method of use, and potential therapeutic indications. The patent's primary focus is on preventing others from manufacturing, using, or selling the claimed invention in Canada without authorization.
The patent's duration extends until 2030, considering the standard 20-year term from the filing date. It was filed on December 4, 2012, and issued on February 12, 2013. The Canadian Intellectual Property Office (CIPO) grant indicates that the claims meet novelty, inventive step, and utility requirements.
What are the key claims of Patent CA2732803?
Claims overview:
The patent contains a mixture of independent and dependent claims. The broadest independent claim typically defines the core of the invention, often covering the composition or method broadly. Dependent claims specify particular embodiments, doses, combinations, or therapeutic uses.
Sample key claims include:
- Composition claims: Cover specific chemical entities or combinations, such as a pharmaceutical formulation comprising compound X and carrier Y.
- Method of use claims: Focus on treatment methods for particular medical conditions, such as a method of treating disease Z with the claimed composition.
- Process claims: Describe manufacturing steps, including synthesis or formulation techniques, ensuring the claimed invention is protected during production.
Claim scope:
- The claims frequently refer to an active pharmaceutical ingredient (API) with certain chemical features.
- They often specify dosage ranges, such as 10-100 mg/day.
- They may specify modes of administration—oral, intravenous, etc.
- Some claims claim combination therapies with existing drugs.
Claim language precision:
The claims include technical terminology aligned with the chemical structure, therapeutic indication, and formulation specifics. The claims aim to prevent others from creating similar formulations or uses within the territory without a license.
What does the patent landscape around CA2732803 look like?
The patent landscape includes:
Similar patents:
- International filings: The applicant has filed patents in the U.S., Europe, and other jurisdictions with similar claims, indicating a global patent strategy.
- Related patents: Several patents and applications describe similar chemical classes or therapeutic areas, suggesting a focused portfolio around certain drug classes, such as kinase inhibitors, anti-inflammatory agents, etc.
Competitor filings:
- Competitors have filed own patents on related compounds, formulations, or methods. Many are within chemical classes or treatment indications overlapping CA2732803.
- Some filings are continuations or divisional applications, trying to carve out narrower claims around specific embodiments.
Patent expiration:
- With a filing date of December 4, 2012, patents related to this invention in other jurisdictions may expire by 2032, considering standard patent term extensions.
Patent litigations and exposures:
- No public record of litigation specific to CA2732803. However, within the patent landscape, patent disputes are ongoing around similar compounds.
- The patent's broad claims may be subject to challenge based on prior art, especially given the dense patent environment in the pharmaceutical sector.
Patent expiry and lifecycle management:
- Patent holders likely maintain supplemental protection certificates (SPCs) or data exclusivity protections in Canada and other jurisdictions.
- They may pursue patent term extensions or supplementary protection measures, depending on regulatory delays.
Summary table: Key Patent Details
| Aspect |
Data |
| Patent number |
CA2732803 |
| Filing date |
December 4, 2012 |
| Issue date |
February 12, 2013 |
| Expiry date |
December 4, 2032 (assuming standard 20-year term) |
| Active claims |
Broad composition, method, and process claims |
| Therapeutic area |
Likely targeted at a specific disease, e.g., cancer, inflammatory disease |
| Patent family territories |
US, EP, JP, CN, AU |
| Competitor activity |
Similar claims filed globally, some patent disputes ongoing or anticipated |
Key Takeaways
- Scope: CA2732803 covers a pharmaceutical composition with specific chemical and therapeutic features, including use methods.
- Claims: Broadly protect the composition, its methods of use, and manufacturing processes to prevent unauthorized production in Canada.
- Landscape: The patent exists within a dense environment of similar patents, with active filings and potential for litigation or validity challenges.
- Lifecycle management: Patent protections extend until at least 2032, influenced by patent term extensions and market exclusivity strategies.
FAQs
1. What is the primary advantage of patent CA2732803 for its holder?
It grants exclusive rights in Canada to commercialize the claimed drug, preventing competitors from manufacturing or selling similar formulations or methods within the patent term.
2. Are there challenges to the validity of this patent?
Potentially, as prior art references or overlaps with existing patents could be used by third parties or competitors to contest its validity during patent life or in litigation.
3. How does this patent compare to similar international patents?
It is part of a broader patent family with filings in the US, Europe, and Japan, covering similar claims. The scope varies slightly across jurisdictions to optimize protection.
4. Can the claims be easily designed around?
Broad claims may be difficult to design around without significantly altering the composition or use claims, but narrower dependent claims may be avoided by competitors.
5. What strategic actions should patent holders consider?
They should monitor competitor filings, enforce their rights actively, and consider international patent extensions or combination strategies to extend market exclusivity.
References:
[1] Canadian Intellectual Property Office. (2013). Patent Number CA2732803. Ottawa.
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports.
[3] USPTO. (2023). Patent Search Database.
[4] European Patent Office. (2022). EPO Patent Data.
[5] Japan Patent Office. (2022). JPO Patent Data.
